Explore By Subject Area   

Lead Editorial

Intellia Therapeutics's CMO on Exciting Developments in In Vivo Gene Editing

Intellia Therapeutics's CMO on Exciting Developments in In Vivo Gene Editing

David Lebwohl, MD, EVP, CMO of Intellia Therapeutics, shares an update on Intellia’s gene editing programs, his approach to educate stakeholders on new modalities and advice for CMOs in cell & gene therapy.

Read More

More Related Content

Editorial

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.